Dr. Min Seob Lee is a chairman of Diagnomics Inc, in California, and currently assuming a responsibility as a CEO of Eone Diagnomics Genome Center (EDGC) in Incheon Korea. Diagnomics is one of the first whole genome sequencing (WGS) based genomics and bioinformatics company started with an expertise in personal genome annotation and interpretation in 2010. EDGC is a joint venture between Eone Life Science and Diagnomics that focuses on clinical and consumer application development using sequencing and array based genome information. He is a president and director of Share Genome Organization in California that promotes researchers and participants to share genomics data and resources to promote next generation healthcare and research revolution. He has founded multiple companies and institutes in Genomics and Personalized Medicine industries including Diagnomics, Eone Diagnomics Genome Center (EDGC), MyGenomeBox (MGB), Genomics Personalized Health (GPH), Precision Biocount, ScaleMatrix Life Science & Technology Center and Share Genome Organization. Dr. Lee is a world renowned researcher and entrepreneur in Genomics and outstanding leader in healthcare and bio-tech industries and its implementation for personalized medicine and diagnostics development. He has extensive global experience and presence in the life sciences, healthcare and IT business area including bio-tech, pharmaceutical and diagnostics companies with expertise in personal genomics, big-data processing, pharmacogenomics, bioinformatics and molecular diagnostic. Prior to the current roles and responsibilities, he held several positions at Sequenom in San Diego within the Diagnostic Development and Molecular Medicine. Earlier, he was in charge of a high throughput HAP Typing and HAP Factory laboratories, and responsible for genomic based molecular test development and performed the high-throughput genome sequencing and genotyping operation at Genaissance Pharmaceuticals in Connecticut. Dr. Lee published numerous articles and has been granted several US, Korea and international patents in the area of personalized medicine, genomics and diagnostic development. He conducted his post-doctoral fellowship at the Genomics and Proteomics Center at Harvard Medical School and Beth Israel Deaconess Medical Center, and received a Ph.D. degree in Bio Science from City of Hope National Medical Center of the Beckman Research Institute in California.
Dr. Charles Cantor is one of the pioneers of the Human Genome Project, and was appointed Chief Scientific Officer at Sequenom Inc. Dr. Cantor was previously the chair and professor of the department of biomedical engineering and biophysics, and director of the Center for Advanced Biotechnology at Boston University. Prior to this Dr. Cantor held positions at Columbia University College of Physicians & Surgeons, and Professor of Molecular Biology, University of California, Berkeley. He was also director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory. Dr. Cantor has published over 400 peer reviewed articles, authored and co-authored over 50 US and international patents, and co-authored a three-volume textbook on biophysical chemistry. He is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.